Justin Zelin
Stock Analyst at BTIG
(1.46)
# 3,314
Out of 4,761 analysts
37
Total ratings
23.53%
Success rate
-0.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Justin Zelin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IBRX ImmunityBio | Initiates: Buy | $6 | $3.42 | +75.44% | 1 | Jan 10, 2025 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $42 | $21.80 | +92.66% | 1 | Dec 13, 2024 | |
| CARM Carisma Therapeutics | Downgrades: Neutral | n/a | $0.45 | - | 2 | Dec 10, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $55 → $62 | $21.85 | +183.75% | 2 | Jul 9, 2024 | |
| JSPR Jasper Therapeutics | Initiates: Buy | $90 | $5.96 | +1,410.07% | 1 | Jul 8, 2024 | |
| TCRX TScan Therapeutics | Initiates: Buy | $12 | $2.17 | +453.00% | 1 | May 16, 2024 | |
| LYRA Lyra Therapeutics | Downgrades: Neutral | n/a | $0.21 | - | 2 | May 6, 2024 | |
| VKTX Viking Therapeutics | Maintains: Buy | $100 → $125 | $34.07 | +266.89% | 4 | Mar 26, 2024 | |
| VSTM Verastem | Assumes: Buy | $27 | $5.68 | +375.35% | 1 | Nov 21, 2023 | |
| MBIO Mustang Bio | Maintains: Buy | $1,000 → $800 | $2.95 | +27,018.64% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $91 | $29.92 | +204.14% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $0.97 | +927.33% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $1.50 | +966.67% | 1 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $37 | $11.06 | +234.54% | 2 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $35 | $16.38 | +113.68% | 1 | Jun 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $90 | $39.70 | +126.70% | 2 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $8.25 | +275.76% | 1 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $16 | $88.08 | -82.40% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.60 | - | 3 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $10 | $2.45 | +308.16% | 3 | Nov 16, 2022 |
ImmunityBio
Jan 10, 2025
Initiates: Buy
Price Target: $6
Current: $3.42
Upside: +75.44%
Enliven Therapeutics
Dec 13, 2024
Initiates: Buy
Price Target: $42
Current: $21.80
Upside: +92.66%
Carisma Therapeutics
Dec 10, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.45
Upside: -
IDEAYA Biosciences
Jul 9, 2024
Maintains: Buy
Price Target: $55 → $62
Current: $21.85
Upside: +183.75%
Jasper Therapeutics
Jul 8, 2024
Initiates: Buy
Price Target: $90
Current: $5.96
Upside: +1,410.07%
TScan Therapeutics
May 16, 2024
Initiates: Buy
Price Target: $12
Current: $2.17
Upside: +453.00%
Lyra Therapeutics
May 6, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.21
Upside: -
Viking Therapeutics
Mar 26, 2024
Maintains: Buy
Price Target: $100 → $125
Current: $34.07
Upside: +266.89%
Verastem
Nov 21, 2023
Assumes: Buy
Price Target: $27
Current: $5.68
Upside: +375.35%
Mustang Bio
Aug 15, 2023
Maintains: Buy
Price Target: $1,000 → $800
Current: $2.95
Upside: +27,018.64%
Aug 11, 2023
Maintains: Buy
Price Target: $85 → $91
Current: $29.92
Upside: +204.14%
Aug 10, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $0.97
Upside: +927.33%
Jul 25, 2023
Initiates: Buy
Price Target: $16
Current: $1.50
Upside: +966.67%
Jul 3, 2023
Maintains: Buy
Price Target: $30 → $37
Current: $11.06
Upside: +234.54%
Jun 26, 2023
Maintains: Buy
Price Target: $34 → $35
Current: $16.38
Upside: +113.68%
Jun 13, 2023
Maintains: Buy
Price Target: $85 → $90
Current: $39.70
Upside: +126.70%
May 17, 2023
Initiates: Buy
Price Target: $31
Current: $8.25
Upside: +275.76%
Mar 28, 2023
Maintains: Buy
Price Target: $10 → $16
Current: $88.08
Upside: -82.40%
Dec 6, 2022
Downgrades: Neutral
Price Target: n/a
Current: $2.60
Upside: -
Nov 16, 2022
Maintains: Buy
Price Target: $21 → $10
Current: $2.45
Upside: +308.16%